Tempus expanded its data-and-AI collaboration with Gilead, adding access to broader multimodal datasets and Tempus’ AI platform for oncology drug development. Tempus said the expanded deal builds on an earlier arrangement that allowed Gilead to use Tempus de-identified patient data for trial design and biomarker strategy. Under the new terms, Gilead gains access to more multimodal information across indications and to Tempus’ Lens analytics suite, which integrates DNA, RNA, and histology slide content and includes AI tools for cohort filtering and clinical trial simulation. Tempus also said it integrated a large language model into Lens to support queries across large datasets. For Gilead, the expanded collaboration is another step toward using real-world evidence and advanced analytics to reduce trial uncertainty and speed up translational decisions, particularly in biomarker-defined oncology strategies.